6-Chloro-1,2,3,4-tetrahydro-quinoline-8-carboxylic acid | 34849-21-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-Chloro-1,2,3,4-tetrahydro-quinoline-8-carboxylic acid
• 英文别名: 6-Chloro-1,2,3,4-tetrahydroquinoline-8-carboxylic acid
• CAS: 34849-21-3
• 化学式: C₁₀H₁₀ClNO₂
• 分子量: 211.648
• InChiKey: NVNHKJALCFASQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• COMPOUNDS SUITABLE AS MODULATORS OF HDL
  申请人：Thombare Pravin S.

  公开号：US20090171091A1

  公开（公告）日：2009-07-02

  Disclosed herein in the embodiments of the present invention are the compounds suitable as modulators of HDL having general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

  本发明实施例中披露的化合物具有一般式（1），适用于高密度脂蛋白(HDL)调节剂，以及其合成中所涉及的新型中间体、其药学上可接受的盐和含有它们的制药组合物。本发明还涉及制备一般式（1）化合物的方法、它们的互变异构体形式、其药学上可接受的盐、含有它们的制药组合物以及其合成中所涉及的新型中间体。
• Novel cyclic anthranilic acid derivatives and process for their preparation
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：EP0310096B1

  公开（公告）日：1995-04-19
• [EN] COMPOUNDS SUITABLE AS MODULATORS OF HDL<br/>[FR] COMPOSÉS APPROPRIÉS COMME MODULATEURS DU HDL
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2008059513A2

  公开（公告）日：2008-05-22

  [EN] Disclosed herein in the embodiments of the present invention are the compounds suitable as modulators of HDL having general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
  [FR] Les modes de réalisation de la présente invention décrivent des composés appropriés comme modulateurs du HDL ayant la formule générale (1), de nouveaux intermédiaires impliqués dans leur synthèse, leurs sels pharmaceutiquement acceptables et des compositions pharmaceutiques les contenant. La présente invention concerne également un procédé de préparation des composés de formule générale (1), de leurs formes tautomères, de leurs sels pharmaceutiquement acceptables, de compositions pharmaceutiques les contenant, et de nouveaux intermédiaires impliqués dans leur synthèse.